However, our proposal of alternate signaling pathways becoming activated is in agreement with more recent studies showing that MAPK-reactivation does not occur in BRAF(V600E) melanoma cells that cycle slowly in vemurafenib. The gene discussed is BRAF; the disease is melanoma.